Joi’s hormone page says progesterone remains important even without a uterus, pointing to sleep, mood and brain health. That is a broader proposition than explaining an added medicine alongside systemic estrogen. A reader needs to know whether the proposed treatment has an individual reason, rather than assume the statement applies after every operation.
Reviewed September 29, 2026, Joi’s public hormone, care and offer pages document actual services and progesterone listings. This article examines the scope of their claims and the purchase periods attached to the prices. It does not report a consultation, personal treatment response or completed order.
A broad benefit claim is not an explanation of individual need
The hormone page connects progesterone without a uterus to brain function, anxiety, sleep and overall hormone balance. Those are provider claims. The page does not supply an individual diagnosis or demonstrate that every person after hysterectomy benefits from a prescription.
FDA’s menopause information cautions against using hormone therapy to prevent problems such as memory loss, heart disease or stroke. A discussion of symptoms is different from a prevention promise. The public benefit language therefore needs a clinician’s explanation of the actual goal, supporting evidence and uncertainties; it cannot establish prevention or a personal indication simply by naming receptors or hormone levels. Patient-survey promotion on the same page is not an independently assessed outcome for the reader. It cannot supply the missing clinical reason for treatment after a particular operation or establish comparative effectiveness.
A genuine exception still has a particular history behind it
The British Menopause Society’s February 2026 endometriosis guidance discusses circumstances in which combined hormone treatment may be considered after hysterectomy in people with endometriosis. It also acknowledges limited high-quality evidence and uncertainty about absolute risks. Residual disease and individual circumstances affect that discussion.
This UK professional guidance is a useful counterexample to an absolute rule that progesterone is never relevant after hysterectomy. It is not evidence that Joi’s broad claim applies to everyone, nor approval of a Joi preparation. Our post-hysterectomy questions keep the exception attached to the relevant history. The publication does not infer disease, residual tissue or a prescription from the surgery name.
Systemic and vaginal listings need separate explanations
Joi’s product overview lists systemic estrogen and vaginal estrogen separately, as well as progesterone. Their appearance on one page does not mean that all three should become part of a single plan.
The NAMS local-treatment abstract says low-dose vaginal estrogen does not require a progestogen, but retains the absence of endometrial safety trials beyond one year. Our local-treatment context preserves that boundary. For a different treatment category, the systemic-estrogen guide asks what accompanying protection is intended. The exact estrogen product and the person’s history must be identified before those two discussions can be meaningfully connected.
Read each price together with what is billed and when
The main hormone page displays progesterone capsules at $54 per month and cream at $69 per month. Medicines are separately charged and both billed and shipped quarterly. The $50 monthly care figure is also billed quarterly and describes clinician visits and follow-up testing. None of these monthly displays establishes a one-month purchase.
Initial laboratory panels are listed at $149, $399 and $699, alongside a sixty-five-percent promotional banner. A separate offer uses fifty-percent language and describes a $35 fee per three-month prescription for certain estrogen and progesterone prescriptions sent to a local pharmacy. Those records should not be combined into an invented final bill or assumed insurance benefit.
The exact preparation remains a separate evidence question
Joi’s safety notice says some medicines may be compounded and not FDA-approved. It does not establish the approval status, full ingredients or manufacturer of every capsule a patient might receive. The difference matters when a public claim about a hormone is applied to a specific preparation.
FDA’s compounding explanation states that compounded drugs do not undergo its premarket approval for safety, effectiveness and quality. That limitation is not proof that every listed medicine is compounded. Wisp’s review examines a menu that leaves a different set of product details unresolved. Both require the actual prescription before a meaningful product-level comparison can be made.
Care-team roles and cancellation wording deserve their own questions
The care page distinguishes coaching support from clinical work; coaches do not diagnose, prescribe or provide medical advice. Help with a care process is therefore different from responsibility for deciding whether a hormone is appropriate.
The hormone page also places cancellation-at-any-time wording near language allowing cancellation after the first three months. The reviewed pages do not resolve which condition governs a selected agreement. Thrivelab’s review likewise separates clinical assessment from ongoing charges. For Joi, neither a reassuring support description nor a monthly equivalent settles the initial commitment, personal access or the professional responsible for reassessment.
A protection or wellness claim cannot interpret new bleeding
ACOG’s bleeding guidance describes the need to evaluate bleeding after menopause and abnormal changes during the transition. The bleeding-and-treatment guide places that assessment ahead of trying to explain the symptom through a sales page.
Joi offers relevant hormone care, but this review cannot confirm how an individual concern would be assessed or whether an in-person examination would be arranged. A useful final explanation would identify the treatment’s purpose, account for the actual history and name the route for clinical questions. It would also distinguish a hoped-for benefit from an established indication and from a result that has not been measured.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Joi + Blokes: hormone care and progesterone listingsProvider capsule versus cream, separate quarterly charges, compounding notice and promotional claims; exact capsule identity, first-lab total and cancellation wording unresolved · Checked 2026-09-29
- FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
- British Menopause Society: Induced Menopause in Women with Endometriosis, February 2026UK professional guidance; specific endometriosis-related exception and limited high-quality evidence, not US approval or individual instructions · Checked 2026-09-29
- North American Menopause Society: 2020 Genitourinary Syndrome of Menopause position statementPublished professional consensus abstract only; low-dose vaginal therapy distinction, lack of endometrial trials beyond one year and breast-cancer evidence limits · Checked 2026-09-29
- Joi + Blokes: separate HRT offerDated distinct offer with different lab promotion and local-pharmacy prescription fee; not silently merged into all current orders · Checked 2026-09-28
- FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
- Joi + Blokes: service and coach rolesDated provider homepage; coach role expressly excludes diagnosis/prescribing/specific medical advice; no individual service result verified · Checked 2026-09-28
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseUS specialty patient guidance reviewed February 2024; bleeding changes require professional assessment, not a site-generated workup or medication adjustment · Checked 2026-09-29